Pacific Biosciences Welcomes Neil Ward to Its Leadership Team as Vice President and General Manager for Europe, Middle East,...
June 08 2021 - 2:00AM
Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading
provider of high-quality, long-read sequencing platforms, today
welcomed Neil Ward to the new role of Vice President and General
Manager for the company’s Europe, Middle East, and Africa (EMEA)
region to expand and develop the team and infrastructure to
capitalize on the immense potential for genomics in this area of
the world.
Neil is a genomics industry veteran with more than two decades
of global experience. He most recently served as Senior Sales
Director for Northern Europe at Illumina. In his various commercial
roles, Neil has served as a key contributor in many of the world’s
largest genomics projects including Genomics England’s 100,000
Genome Project, the Estonian Genome Project, and the whole genome
sequencing of the 500,000 UK Biobank samples. Prior to his 13 years
at Illumina, Neil held bioinformatics and sales roles at leading
institutions, including Agilent, Silicon Genetics, Oxford Biomedica
and Celltech.
“We could not be more thrilled to have Neil join us. His deep
experience and relationships across the genomics ecosystem, as well
as his demonstrable passion for the role genomics can play to
better human health will be invaluable to lead our expansion
strategies in EMEA,” shared Peter Fromen, Chief Commercial Officer
at PacBio.
“I’m grateful and excited for the opportunity to be part of this
exceptional team working to improve the health of the planet
through genomics. PacBio is at an inflection point and we're just
beginning to realize the potential that HiFi data can have on our
understanding of genomics,” said Neil Ward, Vice President and
General Manager of EMEA at PacBio. “As we look forward to the next
decade, I believe this team will help accelerate the utility of
genomics through new applications and insights uncovered by SMRT
Sequencing technology.”
The genomics landscape has grown considerably over the past
decade, and there are more labs than ever performing sequencing.
After years of investment and product development, industry experts
recognize PacBio as a leader in accurate and complete long-read
sequencing. The company’s innovative instruments are based on
Single Molecule, Real-Time (SMRT®) Sequencing technology, which
delivers a comprehensive view of genomes, transcriptomes, and
epigenomes, enabling access to a wide spectrum of genetic variation
in any organism.
Cited in thousands of peer-reviewed publications,
PacBio sequencing systems are in use by scientists around the
world to drive discovery in human biomedical research, plant and
animal sciences, and microbiology. More customers than ever can now
benefit from incorporating PacBio® sequencing into their labs. To
capture this opportunity, we are dramatically increasing the number
of quota-carrying sales representatives - aiming to at least double
the team we had at the end of 2020. Further, we are expanding and
realigning our global commercial infrastructure to support
sustained long-term growth.
About Pacific BiosciencesPacific Biosciences of
California, Inc. (NASDAQ: PACB) is empowering life scientists with
highly accurate long-read sequencing. The company’s innovative
instruments are based on Single Molecule, Real-Time (SMRT®)
Sequencing technology, which delivers a comprehensive view of
genomes, transcriptomes, and epigenomes, enabling access to the
full spectrum of genetic variation in any organism. Cited in
thousands of peer-reviewed publications, PacBio® sequencing systems
are in use by scientists around the world to drive discovery in
human biomedical research, plant and animal sciences, and
microbiology. For more information, please
visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use
Only. Not for use in diagnostic procedures.
Forward-Looking Statements This press release
may contain “forward-looking statements” within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended, and
the U.S. Private Securities Litigation Reform Act of 1995,
including statements relating to the potential for genomics in the
EMEA, the role genomics can play to better human health, the
potential of HiFi data, the applications, insights, and attributes
of SMRT sequencing technology, the benefits of PacBio sequencing,
the Company’s anticipated growth and commercialization efforts,
including headcount increases in sales and marketing, the Company’s
long-term growth prospects, strategic priorities and direction, and
other future events. Readers are cautioned not to place undue
reliance on these forward-looking statements and any such
forward-looking statements are qualified in their entirety by
reference to the following cautionary statements. All
forward-looking statements speak only as of the date of this press
release and are based on current expectations and involve a number
of assumptions, risks and uncertainties that could cause the actual
results to differ materially from such forward-looking statements.
Readers are strongly encouraged to read the full cautionary
statements contained in the Company’s filings with the Securities
and Exchange Commission, including the risks set forth in the
company’s Forms 8-K, 10-K, and 10-Q. The Company disclaims any
obligation to update or revise any forward-looking statements.
Contacts
Investors:Todd Friedman+1 (650)
521-8450ir@pacificbiosciences.com
Media:Jen Carroll+1 (858)
449-8082pr@pacificbiosciences.com
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Apr 2023 to Apr 2024